Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Benchmarking the scientific output of the Innovative Medicines Initiative

Nature Biotechnology volume 33, pages 811–812 (2015)Cite this article

Subjects

To the Editor:

Recent years have witnessed the establishment of over 400 consortia to translate biomedical research advances into new therapies for major unmet needs, such as brain disorders, antimicrobial resistance, diabetes, immune-inflammatory diseases and cancer1. These consortia typically bring together multiple stakeholders, including large and small-sized companies, academic research institutions, public health organizations, regulatory agencies and patient groups. The rationale behind these efforts, many of which are public-private partnerships, is to assemble a critical mass of expertise and resources that can not only solve highly complex challenges of drug discovery and development but also ensure that scientific breakthroughs are exploited by the pharmaceutical industry and regulatory agencies to benefit patients and society. The establishment of public-private consortia is usually based on the definition of a 'precompetitive' space in which private companies agree to share knowledge, investment and risk. One way to measure the performance of such consortia is to use the scientific literature—bibliometrics—as a means for assessing the output and/or quality of partnerships for health innovation. Here, we study the scientific output of the archetypal European precompetitive consortium: the Innovative Medicines Initiative (IMI; Brussels).

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Lim, M.D. Sci. Transl. Med. 6, 242cm6 (2014).

    Article  PubMed  Google Scholar 

  2. Printz, C. Cancer 119, 1925–1927 (2013).

    Article  PubMed  Google Scholar 

  3. Goldman, M., Seigneuret, N. & Eichler, H.-G. Nat. Rev. Drug Discov. 14, 1–2 (2015).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Innovative Medicines Initiative, Brussels, Belgium

    Magda Gunn

  2. Fastercures, Center of the Milken Institute, Washington, DC, USA

    Mark Lim

  3. Thomson Reuters, New York, New York, USA

    Didi Cross

  4. Université Libre de Bruxelles, Brussels, Belgium

    Michel Goldman

Authors
  1. Magda Gunn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Didi Cross
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michel Goldman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Magda Gunn.

Ethics declarations

Competing interests

M.G. is scientific officer at the program office of IMI. D.C. is at Thomson Reuters, which conducted the bibliometric analysis for IMI. M.G. is the former executive director of IMI.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gunn, M., Lim, M., Cross, D. et al. Benchmarking the scientific output of the Innovative Medicines Initiative. Nat Biotechnol 33, 811–812 (2015). https://doi.org/10.1038/nbt.3305

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3305

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing